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To describe the use of antimuscarinic drugs to treat overactive bladder (OAB) in Denmark,
Sweden, and the United Kingdom (UK).
Methods
We identified new users of darifenacin, fesoterodine, oxybutynin, solifenacin, tolterodine,
and trospium aged 18 years or older from the Danish National Registers (2004–2012), the
Swedish National Registers (2006–2012), and UK Clinical Practice Research Datalink
(2004–2012). Users were followed until disenrollment, cancer diagnosis, death, or study
end. Treatment episodes, identified by linking consecutive prescriptions, were described
with respect to duration, drug switch, and drug add-on.
Results
Mean age of OAB drug users was 66 years in Denmark (n = 72,917) and Sweden (n =
130,944), and 62 years in the UK (n = 119,912); 60% of Danish and Swedish patients and
70% of UK patients were female. In Denmark, of 224,680 treatment episodes, 39% were
with solifenacin, and 35% with tolterodine; 2% were with oxybutynin. In Sweden, of 240,141
therapy episodes, 37% were with tolterodine and 35% with solifenacin; 5% were with oxybu-
tynin. In the UK, of 245,800 treatment episodes, 28% were with oxybutynin, 27% with solife-
nacin, and 26% with tolterodine. In the three countries, 49%-52% of treatment episodes
comprised one prescription and over 80% of episodes ended because of no refill; less than
20% ended because of a switch to another antimuscarinic. During the study years, we
observed a change in OAB treatment preference from tolterodine to solifenacin.
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Conclusions
In these cohorts, persistence with antimuscarinic drugs was low. By 2012, the preferred
drug was solifenacin; oxybutynin use was marginal in Nordic countries compared with the
UK.
Introduction
According to the International Continence Society, overactive bladder (OAB) can be defined
as urinary urgency, usually with urinary frequency and nocturia, with or without urgency uri-
nary incontinence [1]. Using this definition, the self-reported prevalence of OAB was 13% in
women and 11% of men in Canada, Germany, Italy, Sweden and the United Kingdom (UK) in
2005 [2]. Studies using non-standardised definitions have reported urgency incontinence
prevalences as low as 2% and as high as 36% worldwide [3]. While treatment with antimuscari-
nic drugs has been reported to improve quality of life, [4] these medications are often discon-
tinued due to side effects or limited efficacy.
The purpose of this study was to describe utilisation patterns of antimuscarinic drugs to
treat OAB in three European populations (Denmark, Sweden, and the UK’s Clinical Practice
Research Datalink [CPRD]) at the time when only antimuscarinic drugs were available for the
treatment of OAB; it was conducted to partially fulfil a regulatory requirement. This study
updates previous reports on the use of these drugs in Denmark and the UK [5–7].
Materials and methods
Ethics statement
This study was judged to be exempt from review by the RTI International institutional review
board and was approved by the Ethical Review Board at Karolinska Institutet, Stockholm (Ref
no.2014/1478-31). In Denmark, pure register studies are exempt from review by an Ethics
Committee. For this type of study patient consent is not required.
Setting
We conducted a cohort study including adults newly exposed to antimuscarinic drugs used to
treat OAB from January 1, 2004, through December 31, 2012, in Denmark and the UK. In
Sweden, the study period started on January 1, 2006 (1 year after dispensed prescriptions
started to be recorded in the Swedish Prescribed Drug Register), and also finished on Decem-
ber 31, 2012. The study drugs were darifenacin, fesoterodine, oxybutynin, solifenacin, toltero-
dine, and trospium (trospium was not available in Sweden; codes are provided in the S1
Table). The diagnosis of OAB was not required for inclusion in the study. In Denmark and
Sweden, we ascertained exposure through dispensed prescriptions, and in the UK with issued
prescriptions. In each country, the study population included all patients aged 18 years or
older with at least 12 months of continuous enrolment in the database followed by a prescrip-
tion for a study drug, provided that the same drug was not prescribed during the previous 12
months. The first recorded prescription that met this criterion was the patient’s index prescrip-
tion. Patients with cancer (except non-melanoma skin cancer) diagnosed prior to the index
prescription were excluded. In Sweden and the UK, subjects with HIV infection prior to the
index prescription were also excluded. This was done in the UK because health care may occur
outside the routine avenues after this diagnosis, and thus health care may not be fully captured.
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Sweden applied this criterion for consistency across data sources. Follow-up started with the
index prescription and ended at the earliest of the end of the study period, cancer diagnosis
(except non-melanoma skin cancer), death, emigration, or disenrollment from the database.
During the study period, the included drugs were authorised for sale only by prescription in
the three countries.
Data sources
In the three countries, we used health information collected during routine health care. In
Denmark, data were collected from the following nationwide registers: the Danish Civil Regis-
try (dates of birth, death, and migration) [8], the Danish National Registry of Patients (hospital
diagnoses) [9], the Danish Cancer Registry (cancer diagnoses) [10], the Cause of Death Regis-
try [11], and the Danish National Prescription Registry (DNPR). The DNPR contains data on
all drugs dispensed to Danish residents since 1995, prescribed by general practitioners or spe-
cialists [12]. The data include information on substance name, brand name, pharmaceutical
form, dispensed quantity of the drug, and date of dispensing. Information on over-the-counter
drugs, drugs administered at hospitals or nursing homes, or drugs prescribed but not dis-
pensed is not recorded in the DNPR.
Swedish nationwide registers used for this study were the Swedish National Patient Register
(hospital diagnoses) [13], the Swedish Cancer Register [14], the Swedish Cause of Death Regis-
ter [15], and the Swedish Prescribed Drug Register [16]. The latter includes Anatomical Thera-
peutic Chemical (ATC) code, brand name, pharmaceutical form, strength, package size,
number of packages dispensed, dispensed number of defined daily doses [17], and prescribing
and dispensing dates. The register does not include over-the-counter medicines, medicines
administered at hospitals and nursing homes, or medicines prescribed but not dispensed.
In the UK, we used data from CPRD GOLD (primary care electronic medical records),
Hospital Episode Statistics (hospital diagnoses), National Cancer Data Repository, and Office
for National Statistics (mortality data). Drug use was ascertained from prescriptions issued by
general practitioners; information includes the substance name, brand name, pharmaceutical
form, strength, British National Formulary coding, dose, and days’ supply.
Statistical analysis
Treatment episodes were identified by linking consecutive prescriptions into a single treat-
ment episode, with slightly different implementations in each country. In Denmark, we
assumed that two prescriptions with dispensing dates falling within a drug-specific interval
were part of the same treatment episode. The duration of these intervals was estimated through
a waiting-time distribution analysis, which is a modelling based on the observed intervals
between dispensings. We constructed these waiting-time–based models specifically for each
drug [18, 19]. Switching and add-ons were defined by an overlap between treatment episodes
for two different OAB drugs. Overlaps longer than 60 days were considered add-ons; shorter
overlaps were considered switches.
In Sweden, therapy episodes were defined based on adjacent dispensings for the same drug
with a gap 60 days between the end of a dispensing and the beginning of the following dis-
pensing. The duration of dispensings was set to the number of tablets, or 7 × (number of
patches)/2 or (dispensed volume of solution)/30 mL. Dispensings longer than 14 days were
extended by 7 days to allow for nonadherence. Dispensings of a different OAB drug within 7
days of an ongoing dispensing or dispensings that ended during an ongoing dispensing were
considered add-ons. All other dispensings of a second OAB drug during current OAB drug
use were classified as switches.
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In the UK, therapy episodes included adjacent prescriptions for the same drug as long as
the gap between the end of a prescription and the beginning of the following prescription did
not exceed 60 days. When the days-of-supply field for a prescription was missing or equal to
zero or days’ supply could not be calculated from other variables on the prescription record,
the days’ supply was imputed as the modal days’ supply for all prescriptions in the study cohort
of the same study drug and strength with nonmissing and nonzero days’ supply. Each therapy
episode was extended by 7 days to allow for nonadherence. Add-ons occurred when patients
started taking another OAB drug while continuing the current OAB therapy. Switches
occurred when patients stopped taking a OAB drug and started taking a different OAB drug in
an adjacent therapy episode, or when patients on more than one OAB drug dropped one or
more of those drugs while continuing to take the other drug(s).
In the three countries, episodes could end due to lack of refill, switch to another drug, addi-
tion of another antimuscarinic drug (“add-on”), or end of follow-up.
We described characteristics of patients and treatment episodes. Patient characteristics
were assessed using all available data before cohort entry. Trends in drug use were shown as
the proportion of patients who entered the cohort on each drug each year (e.g., of the 5,122
patients who entered the cohort in 2004 in Denmark, 3,679 were on tolterodine, representing
72% of the new users of antimuscarinics that year).
This study was registered in the EU PAS Register before the start of data collection (Danish




All study drugs were available as tablets. The cohort included 72,917 patients with a mean age
of 66 years, of whom 60% were women (Table 1). Patient characteristics and morbidity were
similar across drugs, except that patients who entered the cohort on oxybutynin (1%) had a
higher proportion of women (81%) than other drugs. A total of 224,680 therapy episodes were
observed (3.1 episodes per person on average) (Table 2); solifenacin accounted for 39% of
them and tolterodine for 35%. Over the study period, the number of new users of OAB anti-
muscarinics increased from 2004 to 2007 (5,122 to 9,969 new users). By 2012, the number had
decreased to 8,725. Over these years, there was a decrease of new use of tolterodine and an
increase of new use of solifenacin (Fig 1).
Nearly half (49%) of the episodes comprised a single prescription; tolterodine had the larg-
est proportion of single-prescription therapy episodes (54%) and the lowest proportion of epi-
sodes with five or more prescriptions (15%). Nearly all (93%) episodes ended due to lack of
renew or refill. The most common drug switched to or added on was solifenacin. For solifena-
cin drug episodes, the most common drug switched to or added on was tolterodine.
Sweden
Trospium was not available during the study period. All study drugs were available as tablets;
oxybutynin was also available in transdermal patches and as intravesical solution. The cohort
comprised 130,944 patients, with a mean age of 66 years, 60% women (Table 1). Patient char-
acteristics and morbidity were generally similar across drugs, except that patients who entered
the cohort on oxybutynin (4%) were younger on average (mean age 55 years, with a wide dis-
persion), and were somewhat healthier. We observed 240,141 therapy episodes (1.8 episodes
per person on average) (Table 2): 37% with tolterodine and 35% with solifenacin. New use of
the study drugs first increased from 13,223 users in 2006 to 24,173 in 2007, and then decreased
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PLOS ONE | https://doi.org/10.1371/journal.pone.0204456 September 27, 2018 4 / 13
to 16,618 new users in 2012. Over the study period, there was a net decrease in new use of tol-
terodine and an increase in new use of solifenacin and fesoterodine (Fig 1).
Of index therapy episodes, 52% had only one prescription (Table 2). Oxybutynin was the
drug with the largest proportion of single-prescription therapy episodes (62%), the lowest pro-
portion of episodes with five or more prescriptions (13%), and one of the highest prevalences
of use of study drugs (excluding the study drug on which patients entered the cohort) in the 12
months before cohort entry (21%). Of all episodes, 83% ended because the prescription was
Table 1. Patient characteristics by index antimuscarinic OAB drug in Denmark, Sweden, and the UK.
Characteristic All Darifenacin Fesoterodine Oxybutynin Solifenacin Tolterodine Trospium
n % n % n % n % n % n % n %
Denmark
Patients 72,917 2,698 3.7 5,749 7.9 740 1.0 30,792 42.2 23,776 32.6 9,105 12.5
Age in years (median, IQR) 66 (mean) 15.1 (SD) 69 59–78 67 56–76 66 55–76 68 57–77 69 58–78 68 56–77
Women 43,434 59.6 1,768 65.5 3,407 59.3 597 80.7 18,353 59.6 13,812 58.1 5,466 60.0
Hypertensiona 16,051 22.0 561 20.8 1,416 24.6 175 23.6 6,974 22.6 5,012 21.1 1,903 20.9
Diabetesa 5,773 7.9 207 7.7 500 8.7 55 7.4 2,413 7.8 1,881 7.9 713 7.8
Stroke 10,456 14.3 353 13.1 719 12.5 121 16.4 4,179 13.6 3,806 16.0 1,268 13.9
Coronary heart disease 4,340 6.0 152 5.6 315 5.5 33 4.5 1890 6.1 1464 6.2 486 5.3
Heart failure 3,717 5.1 133 4.9 272 4.7 29 3.9 1508 4.9 1344 5.7 425 4.7
Sweden
Patients 130,944 9,093 6.9 13,536 10.3 5,420 4.1 47,313 36.1 55,510 42.4 n/a
Age in years (mean, SD) 66 15.3 67 14.2 65 14.5 55 20.2 65 14.8 68 15.1 n/a
Women 77,992 59.6 5,748 63.2 8,075 59.7 3,409 62.9 30,457 64.4 30,259 54.5 n/a
Hypertensiona 62,492 47.7 4,331 47.6 6,448 47.6 1,905 35.1 22,385 47.3 27,391 49.3 n/a
Diabetesa 14,732 11.3 1,010 11.1 1,532 11.3 455 8.4 5,185 11.0 6,545 11.8 n/a
Stroke 7,445 5.7 563 6.2 724 5.3 159 2.9 2,322 4.9 3,673 6.6 n/a
Coronary heart disease 12,699 9.7 995 10.9 1,326 9.8 367 6.8 4,270 9.0 5,734 10.3 n/a
Heart failure 5,029 3.8 380 4.2 499 3.7 115 2.1 1,630 3.4 2,401 4.3 n/a
UK
Patients 119,912 151 0.1 2,344 2.0 40,651 33.9 33,120 27.6 37,506 31.3 6,071 5.1
Age in years (mean, SD) 62.4 16.7 65.3 14.4 60.1 16.5 62.8 17.4 61.3 16.3 62.8 16.3 64.1 16.1
Women 83,734 69.8 106 70.2 1,642 70.1 27,515 67.7 24,476 73.9 25,740 68.6 4,203 69.2
Smokingb
Never 56,788 47.4 72 47.7 1,098 46.8 19,050 46.9 15,622 47.2 18,018 48.0 2,896 47.7
Former 42,229 35.2 52 34.4 871 37.2 14,448 35.5 12,043 36.4 12,702 33.9 2,093 34.5
Current 19,451 16.2 25 16.6 372 15.9 6,597 16.2 5,313 16.0 6,164 16.4 963 15.9
Hypertensiona 96,738 80.7 126 83.4 1,872 79.9 32,873 80.9 26,645 80.4 30,170 80.4 4,990 82.2
Diabetesa 13,495 11.3 16 10.6 300 12.8 4,711 11.6 3,864 11.7 3,862 10.3 734 12.1
Stroke 8,309 6.9 15 9.9 172 7.3 2,984 7.3 2,044 6.2 2,594 6.9 497 8.2
Coronary heart disease 15,541 13.0 25 16.6 285 12.2 5,309 13.1 4,034 12.2 4,964 13.2 915 15.1
Heart failure 3,869 3.2 9 6.0 64 2.7 1,438 3.5 863 2.6 1,259 3.4 234 3.9
COPD, chronic obstructive pulmonary disease; IQR, interquartile range; n/a, not applicable; OAB, overactive bladder; SD, standard deviation; UK, United Kingdom.
Note: 57, 72, and 69 patients entered the cohort on multiple drugs in Denmark, Sweden, and the UK, respectively (included in the column for all drugs combined).
Counts < 5 subjects not shown. Patient characteristics were assessed using all available data before cohort entry.
a Based on diagnosis or treatment.
b 1.2% of 119,912 patients had unknown smoking status.
https://doi.org/10.1371/journal.pone.0204456.t001
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Table 2. Characteristics of therapy episodes by therapy episode drug in Denmark, Sweden, and the UK.
Characteristic All Darifenacin Fesoterodine Oxybutynin Solifenacin Tolterodine Trospium
n % n % n % n % n % n % n %
Denmark
Therapy episodesa 224,680 9,383 4.2 20,172 9.0 3,616 1.6 87,312 38.9 77,970 34.7 26,227 11.7
Prescriptions per episodeb
1 110,607 49.2 4,013 42.8 9,883 49.0 1,827 50.5 39,861 45.7 41,826 53.6 13,197 50.3
2 43,544 19.4 1,951 20.8 4,092 20.3 655 18.1 17,671 20.2 15,259 19.6 3,916 14.9
3 21,095 9.4 1,041 11.1 1,832 9.1 330 9.1 9,328 10.7 6,239 8.0 2,325 8.9
4 11,858 5.3 626 6.7 1,100 5.5 199 5.5 5,458 6.3 3,076 3.9 1,399 5.3
 5 37,576 16.7 1,752 18.7 3,265 16.2 605 16.7 14,994 17.2 11,570 14.8 5,390 20.6
Therapy episodes ending in a switch to or an add-on with
Any drugc 15,669 7.0 1,026 10.9 1,556 7.7 855 23.6 4,926 5.6 4,608 5.9 2,698 10.3
Darifenacind 1,178 7.5 n/a 114 7.3 103 12.0 432 8.8 314 6.8 215 8.0
Fesoterodined 2,559 16.3 153 14.9 n/a 112 13.1 1,200 24.4 625 13.6 469 17.4
Oxybutynind 1,123 7.2 98 9.6 157 10.1 n/a 458 9.3 244 5.3 166 6.2
Solifenacind 4,827 30.8 357 34.8 658 42.3 313 36.6 n/a 2,440 53.0 1,059 39.3
Tolterodined 3,264 20.8 239 23.3 291 18.7 200 23.4 1,745 35.4 n/a 789 29.2
Trospiumd 2,718 17.3 179 17.4 336 21.6 127 14.9 1,091 22.1 985 21.4 n/a
Sweden
Index therapy episodes 130,944 9,093 6.9 13,536 10.3 5,420 4.1 47,313 36.1 55,510 42.4 n/a
Prescriptions per index therapy episode
1 68,170 52.1 4,338 47.7 6,800 50.2 3,371 62.2 23,143 48.9 30,460 54.9 n/a
2 19,275 14.7 1,527 16.8 1,975 14.6 747 13.8 7,268 15.4 7,746 14.0 n/a
3 9,773 7.5 799 8.8 1,077 8.0 380 7.0 3,705 7.8 3,810 6.9 n/a
4 6,963 5.3 511 5.6 751 5.6 239 4.4 2,749 5.8 2,713 4.9 n/a
 5 26,763 20.4 1,918 21.1 2,933 21.7 683 12.6 10,448 22.1 10,781 19.4 n/a
Previous exposure to study drugse 16,438 12.6 2,071 22.8 1,974 14.6 1,121 20.7 5,971 12.6 5,276 9.5 n/a
Therapy episodes 240,141 17,989 7.5 30,570 12.7 11,813 4.9 83,222 34.7 88,844 37.0 n/a
Therapy episodes ending in a switch to or an add-on with
Any drug 39,894 16.6 4,449 24.7 4,575 15.0 2,789 23.6 10,611 12.8 14,262 16.1 n/a
Darifenacin 4,244 10.6 n/a 454 1.5 414 3.5 1,497 1.8 1,612 1.8 n/a
Fesoterodine 9,943 24.9 1,143 6.4 n/a 567 4.8 3,979 4.8 3,843 4.3 n/a
Oxybutynin 3,631 9.1 453 2.5 562 1.8 n/a 1,235 1.5 1,054 1.2 n/a
Solifenacin 13,317 33.4 1,660 9.2 2,288 7.5 1,024 8.7 n/a 7,625 8.6 n/a
Tolterodine 7,689 19.3 1,163 6.5 1,242 4.1 763 6.5 3,807 4.6 n/a n/a
UK
Index therapy episodes 119,912 140 0.1 2,238 1.9 39,994 33.4 31,856 26.6 36,777 30.7 5,543 4.6
Prescriptions per index therapy episode
1 61,145 51.0 57 40.7 1,028 45.9 22,570 56.4 14,547 45.7 18,340 49.9 2,880 52.0
2 15,682 13.1 13 9.3 347 15.5 5,122 12.8 4,100 12.9 4,426 12.0 655 11.8
3 7,819 6.5 15 10.7 157 7.0 2,378 5.9 2,215 7.0 2,377 6.5 390 7.0
4 4,955 4.1 5 3.6 107 4.8 1,515 3.8 1,466 4.6 1,521 4.1 228 4.1
 5 30,311 25.3 50 35.7 599 26.8 8,409 21.0 9,528 29.9 10,113 27.5 1,390 25.1
Previous exposure to study drugse 5,730 4.8 11 7.9 85 3.8 517 1.3 707 2.2 708 1.9 402 7.3
Therapy episodes 245,800 741 0.3 6,782 2.8 69,581 28.3 65,466 26.6 63,407 25.8 14,308 5.8
Therapy episodes ending in a switch to or an add-on with
Any drug 46,149 18.8 190 25.6 765 11.3 6,348 9.1 5,471 8.4 6,916 10.9 1,643 11.5
Darifenacin 483 1.0 n/a 13 1.7 52 0.8 91 1.7 57 0.8 18 1.1
(Continued)
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not renewed or refilled. The most common drug switched to or added was solifenacin. For
solifenacin treatment episodes, the most common drug switched to or added was tolterodine.
United Kingdom
All study drugs were available as tablets; oxybutynin was also available in transdermal patches
and oral solutions. The cohort comprised 119,912 new users of antimuscarinic OAB drugs
with mean age 62 years, 70% women; 16% were current smokers and 35% were former smok-
ers (Table 1). The distribution of patient characteristics and morbidity was similar across users
of individual drugs.
Index therapy episodes consisted of a single prescription in 51% of episodes, with some var-
iation across individual drugs (Table 2). Oxybutynin had the largest proportion of single-pre-
scription therapy episodes (56%) and the lowest proportion of therapy episodes with five or
more prescriptions (21%). About 5% of index therapy episodes occurred in patients who had
used an antimuscarinic OAB medication (excluding the drug on which the patient entered the
cohort) in the 12 months before cohort entry. Over the study period, we observed 245,800
therapy episodes (2 episodes per person on average). The three most commonly used drugs,
oxybutynin, solifenacin and tolterodine, accounted for 81% of drugs in similar proportions
(Table 2). New use of OAB drugs increased from 12,598 in 2004 to a maximum of 15,441 in
2012. New use of tolterodine decreased over the study period, while new use of oxybutynin
and solifenacin increased (Fig 1).
Overall, 81% of all therapy episodes ended due to lack of renew or refill. For episodes with
any individual drug but solifenacin, the most common drug switched to or added was solifena-
cin (Table 2). For solifenacin therapy episodes, the most common drug switched to or added
was oxybutynin.
Table 2. (Continued)
Characteristic All Darifenacin Fesoterodine Oxybutynin Solifenacin Tolterodine Trospium
n % n % n % n % n % n % n %
Fesoterodine 3,364 7.3 21 11.1 n/a 290 4.6 922 16.9 351 5.1 112 6.8
Oxybutynin 9,964 21.6 45 23.7 188 24.6 n/a 1,911 34.9 2,153 31.1 434 26.4
Solifenacin 15,998 34.7 69 36.3 313 40.9 3,026 47.7 n/a 3,375 48.8 646 39.3
Tolterodine 10,258 22.2 24 12.6 107 14.0 2,396 37.7 1,634 29.9 n/a 431 26.2
Trospium 5,478 11.9 30 15.8 140 18.3 577 9.1 909 16.6 973 14.1 n/a
n/a, not applicable; UK, United Kingdom. Note: For Denmark, therapy episodes with multiple drugs are included in the columns for each of the involved drugs. For
Sweden and the UK, they are counted separately. For Denmark, we present information on number of prescriptions per therapy episode and drugs switched to or added
based on all therapy episodes. For Sweden and the UK, we present information on number of prescriptions based on index therapy episodes and drugs switched to or
added based on all therapy episodes.
a The denominator for percentages in this row is the number of therapy episodes for all drugs combined, presented in the leftmost column (i.e., these are row
percentages).
b The denominator for percentages in the rows for number of prescriptions per therapy episode is the number of episodes for all drugs combined or each individual
drug, as appropriate, presented in the same pair of columns (i.e., these are column percentages).
c The denominator for percentages in this row is the number of therapy episodes for all drugs combined or each individual drug, as appropriate, presented in the same
pair of columns (i.e., these are column percentages).
d The denominator for percentages in these rows is the number of therapy episodes in which there was a switch or add-on for all drugs combined or each individual
drug, as appropriate, presented in the same pair of columns (i.e., these are column percentages).
e In the 12 months before the episode. This information is not available for Denmark.
https://doi.org/10.1371/journal.pone.0204456.t002
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Fig 1. Trends in new use of antimuscarinic drugs for overactive bladder in Denmark, Sweden, and the United Kingdoma a Displayed
are the proportions of patients who entered the cohort with each drug each year.
https://doi.org/10.1371/journal.pone.0204456.g001
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Discussion
The study cohorts in Denmark, Sweden and the UK had similar distributions of age and sex,
with a mean age at cohort entry of 66 years in Denmark and Sweden and 62 years in the UK.
About 60% of the Danish and Swedish patients and 70% of UK patients were women. Patient
characteristics were generally similar across drugs within each country. In all countries, there
was a decreasing trend of new use of tolterodine and increasing new use of solifenacin. In Swe-
den, new use of fesoterodine also increased, and trospium was not available. While use of oxy-
butynin was low in Denmark and Sweden, it accounted for a third of therapy episodes in the
UK, with an upward trend in new use. In the three countries, about half of index episodes had
only one prescription, and over 80% of episodes ended due to lack of renew or refill. Solifena-
cin was the drug most commonly switched to or added.
The use of antimuscarinic OAB drugs has changed over time, as new drugs have become
available and older drugs fall out of preference. In Denmark, based on publicly available data
from the primary sector for users 20 years old or older, only tolterodine was available in year
2000, trospium became available in 2001 and use of darifenacin, oxybutynin, and solifenacin
began later; all following a generally upward trend in use (http://www.medstat.dk/en). In our
data, we observed a decrease in the use of tolterodine and an increase in the use of solifenacin.
Trospium, widely used before, was a less preferred drug in our study. In Sweden, only oxybuty-
nin and tolterodine were available in year 2000 [21]. Until 2006, the use of oxybutynin was rel-
atively low, and the use of tolterodine and the newer solifenacin and darifenacin increased
[21]. From 2006 onward, we observed in Sweden a continuation of those trends, with a peak
number of new users of tolterodine in 2007 (a decreasing trend in the proportion of new users
was already present) and an increase in use of solifenacin and fesoterodine. Use of oxybutynin
was low in our study. In the UK, only oxybutynin was licensed for OAB treatment in 1987.
Until 2002, oxybutynin was the most common OAB drug prescribed to patients with symp-
toms of OAB, and tolterodine was the most common second-line drug. From 2002, tolterodine
was the most common first-line antimuscarinic OAB drug [22]. From 2004 onwards, we
observed a decrease in the use of tolterodine, an increase in the use of solifenacin, and a slight
increase in the use of oxybutynin.
This study was designed to capture patients’ first exposure to any study medication in
patients who were 18 years old or older at any time of the study period. In 13% of index ther-
apy episodes in Sweden and 5% in the UK, exposure to study drugs had been recorded in the
12 months before cohort entry (excluding the study drug on which they entered the cohort).
The proportion of previous use of study drugs varied by drug and by country, probably reflect-
ing changes in drug availability and prescribing preference in each country over time. Clinical
guidelines did not consider any of the study drugs an ideal first-line treatment for all patients;
guidelines recommended tailoring treatments to each patient’s clinical characteristics and con-
comitant medications [23]. Drugs included in this study were given the same level of evidence
and recommendation in the 2010 Guidelines on Urinary Incontinence of the European Asso-
ciation of Urology [23]. During the study years, though, we observed a change in overactive
bladder treatment preference from tolterodine to solifenacin, which was the preferred study
drug by 2012, and oxybutynin use was marginal in the Nordic countries compared with the
UK. We did not find consistent patterns of morbidity that would provide evidence of channel-
ing of patients with a specific morbidity profile to a specific antimuscarinic drug.
Persistence with antimuscarinic drugs was low. In each of the three populations, slightly
over 50% of the index therapy episodes consisted of a single prescription, in line with findings
in a US claims study of patients enrolled in a regional managed care plan with prescription
coverage from 1999 to 2003 [24]. In this study, 45% of patients did not refill their first
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prescription. In another US claims study that identified patients with OAB diagnoses who
started antimuscarinic OAB treatment in 2005–2008, 33% of episodes consisted of a single pre-
scription [25]. A third US claims study in patients with OAB diagnoses who started antimus-
carinic OAB treatment in 2005–2008 reported that 30% of patients with diabetes and 36% of
patients without diabetes stopped treatment after one prescription [26]. In Norway in 2004–
2010, 32% of women who used OAB antimuscarinics filled only one prescription [27]. Studies
evaluating persistence also noted discontinuation of our study drugs at 6 months of more than
50% in Denmark in 1999–2006 [5], 59% in the UK in 1991–2007 [6], and 54%-71% in the UK
in 2007–2008 [7]. A study in Sweden that looked at users of OAB antimuscarinics in 2007–
2008 (2 years in the middle of our study period) reported results similar to ours [28].
A strength of this study is the use of population-based databases covering a period of 9
years (7 in Sweden) and following a common protocol that was locally adapted to the nuances
of each data source. Our data sources include practically the entire populations of Denmark
and Sweden; CPRD reflects the structure of the UK population in terms of sex, age, and ethnic-
ity [29]. The long study period enabled us to see trends in drug use; it remains to be seen how
these change with the approval of new treatments with new mechanisms of action: mirabe-
gron, an oral beta-3 adrenergic receptor agonist, and onabotulinumtoxinA, an injectable ace-
tylcholine release inhibitor and neuromuscular blocking agent.
The main limitation of this study was that we did not have information on treatment dis-
continuation before the end of the prescribed amount, or on the reasons for discontinuation
(side effects are common, and symptom control may require multiple trials of treatment
options [4, 30]). The estimation of duration of prescriptions followed different processes in the
three data sources because the common protocol outlined the estimation process, but allowed
for flexibility so that researchers could apply the methods most appropriate for their data
source. We found similar patterns of drug use in the three data sources, hinting that results
might not be sensitive to the variation in methods. A limitation specific to the UK is that
CPRD only includes prescriptions issued by general practitioners. However, most prescrip-
tions for OAB should be captured, as UK´s National Institute for Health and Care Excellence
(NICE) recommends referral to a specialist only after failure of the first or second OAB drug
[31, 32].
In conclusion, in these three cohorts of new users of antimuscarinic drugs to treat OAB
from Denmark, Sweden and the UK in years 2004–2012, we observed preference for OAB
antimuscarinic treatment changing from tolterodine to solifenacin. Oxybutynin use was mini-
mal in Denmark and Sweden compared with the UK. In all three countries, about half of the
episodes consisted of one prescription. This finding was consistent with those from several
other studies, reflecting that the pattern of use is common to the drug class, with some varia-
tion across individual drugs.
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